Guillain–Barré Syndrome Market - Snapshot

The global Guillain–Barré syndrome market is expanding at a moderate pace, due to increase in the prevalence of Guillain–Barré syndrome across the globe and increasing use of IVIG in off-label indications. The global Guillain–Barré syndrome market was valued at US$ 454.0 Mn in 2016 and is projected to register a compounded annual growth rate (CAGR) of over 5% from 2017 to 2025 to reach value of US$ 708.6 Mn by 2025.

Intravenous immunoglobulins (IVIG) are used for the treatment of Guillain–Barré syndrome. IVIG products such as Gamunex, Gammagard/Kiovig, and Privigen are given in the dose of 0.4 g/kg of body weight per day for five days. Plasma exchange is a proven treatment for Guillain–Barré syndrome. Other treatments such as analgesics, anticonvulsants, and low-molecular-weight heparin are employed to alleviate symptoms and post-treatment complications of Guillain–Barré syndrome. Key driving factors for the market include increase in the incidence of Guillain-Barre syndrome, rise in usage of IVIG in off-label indications, and improved technology for production and purification methods. The number of patients reported with Guillain-Barre syndrome has increased in the last few years. Infection caused by bacterium Campylobacter jejuni is considered to be one of the most common risk factors for developing Guillain-Barre syndrome. The syndrome can also develop after acquiring flu or infection of Cytomegalovirus or Epstein–Barr virus. Guillain-Barre syndrome may develop in the days or weeks following vaccination. According to the Centers for Disease Control & Prevention (CDC), the geriatric population is at a higher risk of developing Guillain-Barre syndrome (GBS), as the incidence of the syndrome increases with age. People aged over 50 years are at the highest risk of developing GBS. Every year, around 3,000 to 6,000 people in the U.S. acquire GBS, whether or not they had received vaccination. The incidence rate is 1 to 2 individuals out of every 100,000 people.

guillain-barre-syndrome-market.jpg

In terms of therapeutics, the market for Guillain-Barre syndrome has been segmented broadly into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). Based on route of administration, the market has been segmented into oral and parenteral. Based on distribution channel, the Guillain-Barre syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Hospital pharmacies is the rapidly expanding segment, owing to increasing incidence of GBS and significant adoption of newer treatments.

Among therapeutics, the intravenous immunoglobulins segment held the largest market share. Intravenous immunoglobulin (IVIG) is a treatment wherein antibodies from donated blood are injected into the patient's vein. IVIG is extensively used due to its ease of administration and favorable side-effect profile. IVIG is administered in doses of 0.4g/kg of body weight per day for 5 days. Unmet needs for management of Guillain-Barre syndrome and promising pipeline of novel molecules and their approval are major factors that are estimated to drive the IVIG segment during the forecast period. Guillain-Barre syndrome is a rare disease. Rare diseases cause a significant financial and medical burden on patients, health care systems, and medical fraternity. Extensive research programs in the field of renal treatment have resulted in several new drugs being developed and approved every year.

Based on geography, the global Guillain-Barre syndrome market has been divided into five major regions: North America, Europe, Asia, Latin America, and Middle East & Africa.  North America and Europe hold the leading share of the global Guillain-Barre syndrome market, followed by Asia Pacific, Latin America, and Middle East & Africa. The U.S. dominates the Guillain-Barre syndrome market in North America. This is majorly due to factors such as high cost of therapeutic products and high awareness among end-users. Also, the market in the U.S. is driven by increased adoption of newly introduced therapeutic drugs and availability of insurance plans for costly treatment of rare diseases in the country. Europe is the second-largest market for Guillain-Barre syndrome. Germany is a major contributor to the Guillain-Barre syndrome market in Europe. The Guillain-Barre syndrome market in Asia Pacific is expanding rapidly, primarily due to presence of developing countries in the region. Growing awareness about rare diseases and expenditure on health care in the region drive the Guillain-Barre syndrome market in Asia Pacific. On the other hand, less penetration of healthcare facilities and lack of availability of products for the treatment of Guillain-Barre syndrome restrain the Guillain-Barre syndrome market in regions such as Latin America and Middle East & Africa.

Key players operating in the global Guillain-Barre syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.

Guillain–Barré Syndrome Market – Overview

This report on the global Guillain–Barré syndrome market studies the current as well as future prospects of the market globally. Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain–Barré syndrome as well as new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain–Barré syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.

Based on therapeutics, the Guillain–Barré syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain–Barré syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain–Barré syndrome and available treatment options for Guillain–Barré syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain–Barré syndrome market and that could also influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies. The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain–Barré syndrome market.

Geographically, the global Guillain–Barré syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides the market size and forecast for major countries in the respective region. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain–Barré syndrome market.

Key players operating in the global Guillain–Barré syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.

The global Guillain–Barré syndrome market has been segmented as follows:

Global Guillain–Barré Syndrome Market, by Therapeutics

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others (Analgesics, Anticonvulsants, LMWH, etc.)

Global Guillain–Barré Syndrome Market, by Route of Administration

  • Oral
  • Parenteral

 Global Guillain–Barré Syndrome Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others (Home Care, Clinics, etc.)

Global Guillain–Barré Syndrome Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • ASEAN
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of World